Role of Immune Therapies for Myeloma.

Role of Immune Therapies for Myeloma. J Natl Compr Canc Netw. 2015 Nov;13(11):1440-7 Authors: Rosenblatt J, Avigan D Abstract Immune therapy has emerged as a promising area of cancer therapeutics based on its potential for tumor selectivity and targeting of chemotherapy-resistant clones. Allogeneic transplantation produces durable remissions in a subset of patients, albeit at the cost of graft- versus-host disease. Recent years have witnessed efforts to induce more selective immune responses via dendritic cell vaccines, autologous and engineered T-cell therapy, and immune checkpoint blockade. Optimizing these immunotherapeutic approaches, understanding how to best use them in combination, and determining how to integrate them with standard anti-myeloma therapy could provide the potential to alter the natural history of this disease. PMID: 26553769 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research

Related Links:

Publication date: Available online 9 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Andrew Tiu, Vinicius Jorge, Peter Moussa, Djeneba Audrey Djibo, Sorab Gupta, Onder Alpdogan, Claudia Dourado
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionMALAT1 is involved in HR pathway by protecting BRCA1 and targeting MALAT1 induces DNA damages in NSCLC.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
There is persistent racial disparities in survival among patients with Diffuse Large B Cell Lymphoma. We conducted a cohort study of 181 patients for 10 years in a single community-based inner-city cancer center. Blacks had decreased overall survival compared to non-Blacks even after excluding patients with HIV and who did not receive chemotherapy. R-IPI score alone could not predict worse outcomes and increased mortality in Blacks with DLBCL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Conclusions Although the laboratory information system’s contribution to the completeness of Cancer Registry incident cases was modest, it is useful to add laboratory data to routine cancer registry information flows due to the increasing use of molecular characterisation and to the phenomenon of dehospitalisation.
Source: European Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Cancer Registries Source Type: research
Colon perforations are rare in MM and here we report characteristics and clinical outcomes of 30 patients that were treated at Mayo Clinic. We believe that steroids are the precipitating factor. AbstractGastrointestinal complications of multiple myeloma (MM) treatment are common and include nausea, constipation, and diarrhea. However, acute gastrointestinal events like perforations are rare. We aimed to describe the characteristics and outcomes of patients with MM that had colonic perforations during their treatment. This is a retrospective study that included patients from all three Mayo Clinic sites who had MM and develo...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
This article has been retracted. Please see the retraction notice for more detail:
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Meletios A. Dimopoulos Due to increased immunoglobulin production and uncontrolled proliferation, multiple myeloma (MM) plasma cells develop a phenotype of deregulated unfolded protein response (UPR). The eIF2-alpha kinase 3 [EIF2αK3, protein kinase R (PKR)-like ER kinase (PERK)], the third known sensor of endoplasmic reticulum (ER) stress, is a serine-threonine kinase and, like the other two UPR-related proteins, i.e., IRE1 and ATF6, it is bound to the ER membrane. MM, like other tumors showing uncontrolled protein secretion, is highly dependent to UPR for survival; thus, inhibition of PERK can be an effect...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Prajwal Dhakal, Elizabeth Lyden, Kate-Lynn E. Muir, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj Bhatt
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ar SK Abstract BACKGROUND: Rearrangements involving the MYC protooncogene are common in newly diagnosed multiple myeloma (MM), but their prognostic significance is still unclear. The purpose of this study was to assess the impact of MYC rearrangement on clinical characteristics, treatment response, and survival in newly diagnosed MM. PATIENTS AND METHODS: This is a retrospective study including 1342 patients seen in Mayo Clinic in Rochester, MN, from January 2006 to January 2018, and who had cytogenetic testing by fluorescence in-situ hybridization at diagnosis, including MYC testing using the break apart FIS...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Blood Cancer Journal, Published online: 02 October 2020; doi:10.1038/s41408-020-00363-6Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Myeloma | Transplants | Vaccines